Please assess the completion status of the following clinical trial:

Trial Title: An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Male and non-pregnant female patients meeting all of the following criteria are eligible for enrollment in this study:~* Patient has completed the Month 18 visit of Study Fx-005.~* If female, patient is post-menopausal, surgically sterilized, or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide) throughout the study. (A condom alone is not considered an acceptable method of birth control.) If male with a female partner of childbearing potential, willing to use an acceptable method of birth control for the duration of the study. For both females and males, acceptable birth control must be used for at least 3 months after the last dose of study medication.~* Patient is, in the opinion of the investigator, willing and able to comply with the study medication regimen and all other study requirements.~* Patient agrees not to participate in another investigational drug or device study while participating in this open-label extension study.~Exclusion Criteria:~Patients meeting any of the exclusion criteria will not be enrolled in the study:~* Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs), defined as greater than 3-4 times/month (ibuprofen and nimesulide will be permitted).~* If female, patient is pregnant or breast feeding.~* Patient has liver function test abnormalities: alanine transaminases (ALT) and/or aspartate transaminases (AST) \>2 times upper limit of normal (ULN) that in the medical judgment of the investigator are due to reduced liver function or active liver disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Fx-1006A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).